(Total Views: 569)
Posted On: 01/20/2021 12:58:44 PM
Post# of 72440
email rec'd @ 12:32PM
Shareholder Alert: Rise of Coronavirus Variants
Wed, Jan 20, 2021 12:32 pm
Innovation Pharmaceuticals info@IPharmInc.comHide
Shareholder Alert: Rise of Coronavirus Variants
Innovation Pharmaceuticals (IPIX) posted today an update to its website, linked below, discussing the emergence of new coronavirus variants, which are raising concerns among scientists and public health officials worldwide. Early data suggests these variants might lessen vaccine efficacy and potentially even escape the body’s immune response.
http://www.ipharminc.com/new-blog/2021/1/20/t...une-escape
This worrisome situation illustrates a large, and likely prolonged, unmet need for COVID-19 therapeutics to supplement the use of vaccines, as the coronavirus continues to evolve and adapt. Innovation will be initiating a Phase 2, randomized, placebo-controlled clinical trial, enrolling hospitalized patients with moderate-to-severe COVID-19, to further evaluate Brilacidin’s COVID-19 treatment potential.
4kids
Shareholder Alert: Rise of Coronavirus Variants
Wed, Jan 20, 2021 12:32 pm
Innovation Pharmaceuticals info@IPharmInc.comHide
Shareholder Alert: Rise of Coronavirus Variants
Innovation Pharmaceuticals (IPIX) posted today an update to its website, linked below, discussing the emergence of new coronavirus variants, which are raising concerns among scientists and public health officials worldwide. Early data suggests these variants might lessen vaccine efficacy and potentially even escape the body’s immune response.
http://www.ipharminc.com/new-blog/2021/1/20/t...une-escape
This worrisome situation illustrates a large, and likely prolonged, unmet need for COVID-19 therapeutics to supplement the use of vaccines, as the coronavirus continues to evolve and adapt. Innovation will be initiating a Phase 2, randomized, placebo-controlled clinical trial, enrolling hospitalized patients with moderate-to-severe COVID-19, to further evaluate Brilacidin’s COVID-19 treatment potential.
4kids
Quote:
Just got this email from IPIX. Did anyone get it earlier than this? 12:35 p.m. eastern time
Quote:
Shareholder Alert: Rise of Coronavirus Variants
Innovation Pharmaceuticals (IPIX) posted today an update to its website, linked below, discussing the emergence of new coronavirus variants, which are raising concerns among scientists and public health officials worldwide. Early data suggests these variants might lessen vaccine efficacy and potentially even escape the body’s immune response.
www.ipharminc.com/new-blog/2021/1/20/t...une-escape
This worrisome situation illustrates a large, and likely prolonged, unmet need for COVID-19 therapeutics to supplement the use of vaccines, as the coronavirus continues to evolve and adapt. Innovation will be initiating a Phase 2, randomized, placebo-controlled clinical trial, enrolling hospitalized patients with moderate-to-severe COVID-19, to further evaluate Brilacidin’s COVID-19 treatment potential.
(5)
(1)Scroll down for more posts ▼
